重视血管co-option在肝癌治疗中的潜在机制及治疗靶点作用  

Mechanisms of vascular co-option as a potential therapeutic target in hepatocellular carcinoma

作　　者：齐明皓 李景涛 翟博[1] Ming-Hao Qi;Jing-Tao Li;Bo Zhai(Department of General Surgery,The Fourth Affiliated Hospital of Harbin Medical University,Harbin 150000,Heilongjiang Province,China)

机构地区：[1]哈尔滨医科大学附属第四医院普外科,黑龙江省哈尔滨市150000

出　　处：《世界华人消化杂志》2024年第11期827-834,共8页World Chinese Journal of Digestology

基　　金：黑龙江省卫生健康委科研课题,No.20220404011082.

摘　　要：肝细胞癌(hepatocellular carcinoma,HCC)是最常见的癌症之一.HCC起病隐匿,多数患者首次诊断时已丧失根治性手术的机会,系统性的抗肿瘤治疗成为中晚期HCC治疗的关键.其中抗肿瘤药物出现耐药性是HCC疗效不佳,影响HCC患者预后的重要原因之一,如何改善HCC的治疗效果仍是现今研究的重点.尽管国内外对以新生血管生成为基础的抗肿瘤药物的研究不断深入,但对共用正常组织血管来满足肿瘤自身代谢需求的血管共选择(vascular co-option)模式研究较少,其对HCC的进展及抗肿瘤治疗的影响也未被人考虑在内.本文就血管co-option对HCC多种治疗方式的影响及相关机制进行概述,以期为改善HCC耐药奠定理论基础.Hepatocellular carcinoma(HCC)is one of the most common cancers,which has an insidious onset,and most of the patients have already lost the chance of radical surgery at the time of the first diagnosis,so systematic antitumor therapy has become the key to the treatment of intermediate and advanced HCC.The emergence of drug resistance to antitumor drugs is one of the most important reasons for the poor efficacy,which affects the prognosis of HCC patients,and how to improve the therapeutic efficacy for HCC is still the main focus of the present research.Although the research on antitumor drugs based on neovascularization has been deepening both domestically and abroad,less research has been done on the vascular co-option mode,which shares blood vessels of normal tissues to meet the metabolic needs of the tumor itself,and its impact on the progression of HCC and antitumor therapy has not been extensively studied.In this paper,we provide an overview of the impact of vascular co-option on multiple treatment modalities for hepatocellular carcinoma and related mechanisms,with a view to laying a theoretical foundation for improving drug resistance in HCC.

关 键 词：肝癌 肿瘤耐药 血管co-option 新生血管生成 抗血管生成治疗 免疫治疗 

分 类 号：R735.7[医药卫生—肿瘤]